Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 265-274

  Wen, Jing ^a,b   Zheng, Bin ^a,b   Hu, Yi ^a,b   Zhang, Xu ^a,b   Yang, Hong ^a,b   Li, Yan ^b   Zhang, Chun Yu ^b   Luo, Kong Jia ^a,b   Zang, Xing ^a,b   Li, Yong Feng ^a,b   Guan, Xin Yuan ^b   Fu, Jian Hua ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Esophageal squamous cell carcinoma; Multidrug resistance; Proteomics

Indexed keywords

40S RIBOSOMAL PROTEIN SA; ACETYL COENZYME A ACETYLTRANSFERASE; ALPHA ENOLASE; BETA ENOLASE; BETA TUBULIN; CISPLATIN; CYSTATHIONINE GAMMA LYASE; CYTOSKELETON PROTEIN; DIHYDROXYACETONE KINASE; DNA DIRECTED DNA POLYMERASE DELTA 2; FATTY ACID BINDING PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; ISOCHORISMATASE DOMAIN CONTAINING PROTEIN 1; LEUKOCYTE ELASTASE INHIBITOR; LIPOCORTIN 1; PHOSPHOSERINE PHOSPHATASE; PROFILIN I; PROLINE SYNTHETASE CO TRANSCRIBED BACTERIAL HOMOLOG PROTEIN; PROTEIN; PROTEIN DISULFIDE ISOMERASE A3 PRECURSOR PROTEIN; PROTEIN PRECURSOR; PROTEIN S100 A11; PROTEIN S100 A4; RETICULOCALBIN 1 PRECURSOR PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN; START DOMAIN CONTAINING PROTEIN 3; THIOREDOXIN; THIOREDOXIN DOMAIN CONTAINING PROTEIN 4 PRECURSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN;

ARTICLE; CALCIUM BINDING; CANCER CELL CULTURE; DNA REPAIR; DNA REPLICATION; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FUNCTIONAL PROTEOMICS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; METABOLISM; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL ELECTROPHORESIS; VALIDATION STUDY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; CYSTATHIONINE GAMMA-LYASE; CYTOSKELETON; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOPLASMIC RETICULUM; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 74549121530     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000497     Document Type: Article

References (31)

1. Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (Suppl 8): S4-S66, 2001.
2. Siewert JR and Ott K: Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17: 38-44, 2007.
3. Stein HJ, Sendler A, Fink U and Siewert JR: Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 80: 659-682, 2000.
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J and Australasian Gastro-Intestinal Trials G: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007.
5. Izzo JG, Malhotra U, Wu TT, et al: Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24: 748-754, 2006.
6. Vallbohmer D and Lenz HJ: Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 19: 425-432, 2006.
7. Tanaka E, Hashimoto Y, Ito T, et al: The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 13: 1331-1340, 2007.
8. Nam TK, Lee JH, Cho SH, et al: Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett 260: 109-117, 2008.
9. Zhang S, Ding F, Luo A, et al: XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 6: 973-980, 2007.
10. Wang H, Qian H, Yu J, et al: Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther 5: 380-385, 2006.
11. Liu TL, Shimada H, Ochiai T, et al: Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-κB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis 11: 1025-1037, 2006.
12. Toshimitsu H, Hashimoto K, Tangoku A, et al: Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells. Cancer Lett 211: 69-78, 2004.
13. Zhang JT and Liu Y: Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 33: 741-756, 2007.
14. Wen J, Zheng B, Hu Y, et al: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep 22: 65-71, 2009.
15. Fu L, Qin YR, Xie D, et al: Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 110: 2672-2681, 2007.
16. Molloy MP, Brzezinski EE, Hang J, McDowell MT and VanBogelen RA: Overcoming technical variation and biological variation in quantitative proteomics. Proteomics 3: 1912-1919, 2003.
17. Berger AC, Farma J, Scott WJ, et al: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337, 2005.
18. Kelsen DP, Winter KA, Gunderson LL, et al: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25: 3719-3725, 2007.
19. Mandic A, Hansson J, Linder S and Shoshan MC: Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100-9106, 2003.
20. Ellgaard L and Frickel EM: Calnexin, calreticulin, and ERp57: teammates in glycoprotein folding. Cell Biochem Biophys 39: 223-247, 2003.
21. Anelli T, Alessio M, Mezghrani A, Simmen T, Talamo F, Bachi A and Sitia R: ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family. EMBO J 21: 835-844, 2002.
22. Higo T, Hattori M, Nakamura T, Natsume T, Michikawa T and Mikoshiba K: Subtype-specific and ER lumenal environment-dependent regulation of inositol 1,4,5-trisphosphate receptor type 1 by ERp44. Cell 120: 85-98, 2005.
23. 2+-dependent redox modulation of SERCA 2b by ERp57. J Cell Biol 164: 35-46, 2004.
24. Orrenius S, Zhivotovsky B and Nicotera P: Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552-565, 2003.
25. Qiu XB, Shao YM, Miao S and Wang L: The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 63: 2560-2570, 2006.
26. Lee AS: GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67: 3496-3499, 2007.
27. Li J and Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6: 45-54, 2006.
28. Ma Y and Hendershot LM: The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4: 966-977, 2004.
29. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
30. Saga Y, Hashimoto H, Yachiku S, Iwata T and Tokumitsu M: Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int J Urol 11: 407-415, 2004.
31. Levonen AL, Lapatto R, Saksela M and Raivio KO: Human cystathionine gamma-lyase: developmental and in vitro expression of two isoforms. Biochem J 347: 291-295, 2000.